The use of immune checkpoint inhibitors (ICIs) has represented a major advance in cancer
treatment. By enhancing endogenous immune responses to destroy cancer cells, ICIs can …

Immune checkpoint inhibitors (ICIs) have made a breakthrough in cancer therapy. Patients
treated with ICIs may develop immune‐related adverse events (irAEs) due to the …

Abstract Purpose of Review This review highlights the spectrum of neurologic adverse
events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the …

Introduction Immunomodulatory therapies, including the use of immune checkpoint inhibitors
(ICIs), have made a profound impact on treatment of advanced cancers in recent decades …

Abstract Purpose of Review Immune checkpoint inhibitors represent a major step forward in
the field of oncologic immunotherapy these last years and have significantly increased …

Abstract Background Immune checkpoint inhibitors (ICIs) are a promising class of anticancer
drugs associated with immune-related adverse events (IRAEs). In registration studies of …

Neurological, immune-related adverse events (n-irAE) due to immune checkpoint inhibitors
(ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the …

As the use of cancer immunotherapy with immune checkpoint inhibitors (ICIs) is expanding
rapidly for the treatment of many tumor types, it is crucial that both neurologists and …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) represent an innovative
therapeutic approach of oncologic diseases. In Europe, this therapeutic class currently …